AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains

Over 120 FDA-approved antibody-based therapeutics are used to treat a variety of diseases.However, many candidates could fail because of unfavorable physicochemical properties. Light-chain amyloidosis is one form of aggregation that can lead to severe safety risks in clinical development. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yuwei, Huang, Ziru, Gou, Yushu, Liu, Siqi, Yang, Wei, Zhang, Hongyu, Dzisoo, Anthony Mackitz, Huang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365155/
https://www.ncbi.nlm.nih.gov/pubmed/37492587
http://dx.doi.org/10.1093/abt/tbad007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365155/
https://www.ncbi.nlm.nih.gov/pubmed/37492587
http://dx.doi.org/10.1093/abt/tbad007

Ejemplares similares